Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2006 1
2007 1
2012 2
2013 3
2014 1
2015 9
2016 7
2017 6
2018 3
2019 3
2020 8
2021 16
2022 12
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Eribulin mesylate exerts antitumor effects via CD103.
Oya K, Nakamura Y, Watanabe R, Tanaka R, Ichimura Y, Kubota N, Matsumura Y, Tahara H, Okiyama N, Fujimoto M, Nomura T, Fujisawa Y. Oya K, et al. Among authors: kubota n. Oncoimmunology. 2023 May 27;12(1):2218782. doi: 10.1080/2162402X.2023.2218782. eCollection 2023. Oncoimmunology. 2023. PMID: 37261089 Free PMC article.
Loricrin and NRF2 Coordinate Cornification.
Ishitsuka Y, Ogawa T, Nakamura Y, Kubota N, Fujisawa Y, Watanabe R, Okiyama N, Fujimoto M, Roop DR, Ishida-Yamamoto A. Ishitsuka Y, et al. Among authors: kubota n. JID Innov. 2021 Oct 15;2(1):100065. doi: 10.1016/j.xjidi.2021.100065. eCollection 2022 Jan. JID Innov. 2021. PMID: 35024686 Free PMC article.
Novel disinfectant olanexidine gluconate-induced contact dermatitis.
Miyahara H, Kubota N, Furuta J, Iijima S, Nomura T. Miyahara H, et al. Among authors: kubota n. J Eur Acad Dermatol Venereol. 2023 Apr 5. doi: 10.1111/jdv.19097. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 37016966 No abstract available.
Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash.
Ichimura Y, Konishi R, Shobo M, Inoue S, Okune M, Maeda A, Tanaka R, Kubota N, Matsumoto I, Ishii A, Tamaoka A, Shimbo A, Mori M, Morio T, Kishi T, Miyamae T, Tanboon J, Inoue M, Nishino I, Fujimoto M, Nomura T, Okiyama N. Ichimura Y, et al. Among authors: kubota n. Rheumatology (Oxford). 2022 Mar 2;61(3):1222-1227. doi: 10.1093/rheumatology/keab518. Rheumatology (Oxford). 2022. PMID: 34152410
Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
Okiyama N, Ichimura Y, Shobo M, Tanaka R, Kubota N, Saito A, Ishitsuka Y, Watanabe R, Fujisawa Y, Nakamura Y, Murakami A, Kayama H, Takeda K, Fujimoto M. Okiyama N, et al. Among authors: kubota n. Ann Rheum Dis. 2021 Sep;80(9):1201-1208. doi: 10.1136/annrheumdis-2020-218661. Epub 2021 Apr 2. Ann Rheum Dis. 2021. PMID: 33811031
The Role of PD-L1 on Langerhans Cells in the Regulation of Psoriasis.
Tanaka R, Ichimura Y, Kubota N, Konishi R, Nakamura Y, Mizuno S, Takahashi S, Fujimoto M, Nomura T, Okiyama N. Tanaka R, et al. Among authors: kubota n. J Invest Dermatol. 2022 Dec;142(12):3167-3174.e9. doi: 10.1016/j.jid.2022.06.006. Epub 2022 Jul 6. J Invest Dermatol. 2022. PMID: 35803322 Free article.
68 results